An observational follow-up study of denosumab in postmenopausal women who successfully completed eight years of the parent and extension study.
Latest Information Update: 01 Nov 2017
At a glance
- Drugs Denosumab (Primary)
- Indications Postmenopausal osteoporosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen
Most Recent Events
- 01 Nov 2017 New trial record